方法：通过回顾性研究，对2013-09/2014-10确诊为Ⅰ区阈值期ROP并行玻璃体注射bevacizumab治疗的26例患儿分三组(阈值前期Ⅰ型ROP、阈值期ROP、急进型后极部早产儿视网膜病变-APROP)，进行术后效果分析比较。

结果：治疗Ⅰ区高危性阈值期ROP患儿26例52眼。其中阈值前期Ⅰ型ROP 3例6眼，阈值期ROP 15例30眼，APROP 8例16眼。治疗阈值期Ⅰ型ROP、阈值期ROP和APROP的一次手术治愈率分别为100%(6/6)、60%(18/30)和75%(12/16)，三组之间手术治愈率无统计学差异(P>0.05)。

结论：玻璃体腔内注射bevacizumab治疗Ⅰ区ROP的临床疗效明确，比传统光凝术治疗具有一定优越性，可作为I区ROP的一线治疗方法。

METHODS:A retrospective study. Totally 26 ROP infants between September 2013 and October 2014 diagnosed as high-risk ROP in Zone Ⅰ had been treated with intravitreal bevacizumab. They were divided into three groups, pre-threshold ROP, threshold ROP and acute posterior ROP(APROP). Postoperative effects were compared.

RESULTS:There were 26 infants(52 eyes)diagnosed as ROP in Zone Ⅰ, including 3 infants( 6 eyes)with pre-threshold ROP, 15 infants(30 eyes)with threshold ROP and 8 infants(16 eyes)with APROP. The first operation recovery rate of three groups respectively were 100%(6/6), 60%(18/30)and 75%(12/16), which were not significantly different(P>0.05).

CONCLUSION:Intravitreal bevacizumab for ROP in Zone Ⅰ seems effective and has some advantages over conventional laser treatment, which could be first line treatment for high-risk ROP in Zone Ⅰ.